Sponsored By:

3 Pharmaceutical Stocks to Buy Now

LCI, PRGO, WPI improve in weekly rankings

   
3 Pharmaceutical Stocks to Buy Now

The grades of three Pharmaceutical stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

This week, Lannett Co. (AMEX:LCI) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Lannett manufactures and distributes pharmaceutical products under its own trade name and under generic names. In Portfolio Grader’s specific subcategories of Earnings Growth, Earnings Revisions, Earnings Surprise, Margin Growth, and Sales Growth, LCI also gets A’s. For more information, get Portfolio Grader’s complete analysis of LCI stock.

Perrigo (NASDAQ:PRGO) is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. Perrigo develops, manufactures, and distributes over-the-counter and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients, and medical diagnostic products. Shares of PRGO have increased 7.7% over the past month, better than the 2.2% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of PRGO stock.

Watson Pharmaceuticals (NYSE:WPI) shows solid improvement this week. The company’s rating rises from a B to an A. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, http://investorplace.com/2013/02/3-pharmaceutical-stocks-to-buy-now-lci-prgo-wpi/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.